Martin Fenner

Publications

• Article-Level Metrics Hannover Medical School DOI: 10.6084/M9.FIGSHARE.681737
• D2.1 Kick off preparation, Communication plan and Website DOI: 10.6084/M9.FIGSHARE.154691
• Publication FP7 Funding Acknowledgment - PLOS OpenAIRE DOI: 10.5281/ZENODO.1239
• TEST Kickoff report DOI: 10.6084/M9.FIGSHARE.107019
• One-click science marketing DOI: 10.1038/nmat3283
• Wie kann die Bibliothek die Sichtbarkeit ihrer Wissenschaftler erhöhen? DOI: 10.3205/12AGMB03
• CrowdoMeter Tweet Classifications DOI: 10.6084/M9.FIGSHARE.90829
• CrowdoMeter Tweets DOI: 10.6084/M9.FIGSHARE.90828
• Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST) DOI: 10.1186/1471-2407-12-186
• ORCID: A system to uniquely identify researchers DOI: 10.1087/20120404
• Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma DOI: 10.1016/j.ejca.2012.02.048
• ORCID: Unique Identifiers for Authors and Contributors DOI: 10.3789/isqv23n3.2011.3
• Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC DOI: 10.1159/000328575
• Key issue Collective action for the open researcher & contributor ID (ORCID) DOI: 10.1629/24277
• Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: A Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study DOI: 10.1093/annonc/mdr026
• Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: A single center experience with 14 patients DOI: 10.1007/s00345-010-0642-3
• Retrospective analyses of patient characteristics having predictive impact on survival under everolimus DOI: 10.1159/000324668
• Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies DOI: 10.1038/bjc.2011.389
• Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer DOI: 10.1007/s00345-010-0527-5
• Reference management meets web 2.0 DOI: 10.3205/ctt-2010-en-000087.01
• Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15INK4b gene methylation and high global DNA methylation DOI: 10.1007/s00277-008-0584-7
• Erythropoietin in cancer-related anemia DOI: 10.1097/CCO.0b013e3283136971
• Blogs, Wikis und Podcasts im Unterricht DOI: 10.1002/biuz.200890080
• Targeted therapies for patients with germ cell tumors DOI: 10.1517/13543784.17.4.511
• Duplication: stop favouring applicant with longest list DOI: 10.1038/452029a
• European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II DOI: 10.1016/j.eururo.2007.12.025
• European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I DOI: 10.1016/j.eururo.2007.12.024
• Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARα/γ ligand TZD18 DOI: 10.1182/blood-2005-05-2103
• Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer DOI: 10.1517/13543784.14.6.557
• Peroxisome proliferator-activated receptor γ ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia DOI: 10.1016/j.leukres.2003.07.005
• Ligands for PPARγ and RAR cause induction of growth inhibition and apoptosis in human glioblastomas DOI: 10.1023/B:NEON.0000003728.80052.a8
• PPARγ ligands and ATRA inhibit the invasion of human breast cancer cells in vitro DOI: 10.1023/A:1023366117157
• Chemotherapy for breast cancer brain metastases DOI: 10.1159/000067443
• Novel therapeutic approach: Ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells DOI: 10.1023/A:1016114026769
• X inactivation in the mouse embryo deficient for Dnmt1: Distinct effect of hypomethylation on imprinted and random X inactivation DOI: 10.1006/dbio.2000.9823
• MSG1 (melanocyte-specific gene 1): Mapping to chromosome Xq13.1, genomic organization, and promoter analysis DOI: 10.1006/geno.1998.5383
• Regulation of expression of MSG1 melanocyte-specific nuclear protein in human melanocytes and melanoma cells DOI: 10.1006/excr.1998.4123
• Transcriptional activating activity of Smad4: Roles of SMAD hetero-oligomerization and enhancement by an associating transactivator
• MSG1 and its related protein MRG1 share a transcription activating domain DOI: 10.1016/S0378-1119(97)00551-9
• Early events of metastasis in the microcirculation involve changes in gene expression of cancer cells: Tracking mRNA levels of metastasizing cancer cells in the chick embryo chorioallantoic membrane
• Experimental animal model of hematogenous cardiac metastasis and neoplastic cardiac tamponade DOI: 10.1002/(SICI)1096-9098(199702)64:2<122::AID-JSO6>3.0.CO;2-D
• Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-α: Evidence of a risk-benefit advantage of subcutaneous therapy
• European studies of interleukin-2 in metastatic renal cell carcinoma
• Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell cancer
• Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma
• Limited efficacy of interferon-α and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinoma
• Neuropsychiatric symptoms during treatment with interleukin-2 and interferon-α [8]